{"id":"NCT01955837","sponsor":"Taiho Pharmaceutical Co., Ltd.","briefTitle":"Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia","officialTitle":"Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2016-02-16","completion":"2016-06-30","firstPosted":"2013-10-08","resultsPosted":"2020-11-17","lastUpdate":"2020-11-17"},"enrollment":406,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"TAS-102","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TAS-102","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.","primaryOutcome":{"measure":"Overall Survival（OS）","timeFrame":"Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.","effectByArm":[{"arm":"TAS-102（Trifluridine/Tipiracil）","deltaMin":7.8,"sd":null},{"arm":"Placebo","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.035"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":null},"locations":{"siteCount":4,"countries":["China","South Korea","Thailand"]},"refs":{"pmids":["29215955"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":63,"n":271},"commonTop":["Anaemia","Nausea","White blood cell count decreased","Decreased appetite","Neutropenia"]}}